Fanny Krantz

655 total citations
12 papers, 495 citations indexed

About

Fanny Krantz is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Fanny Krantz has authored 12 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Fanny Krantz's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Fanny Krantz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Fanny Krantz collaborates with scholars based in United States, Denmark and United Kingdom. Fanny Krantz's co-authors include Raquel Izumi, Todd Covey, Michael Gulrajani, Allard Kaptein, Roger G. Ulrich, Bart van Lith, Tjeerd Barf, Bas van de Kar, Edwin de Zwart and Diana Mittag and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Fanny Krantz

11 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fanny Krantz United States	7	401	300	147	129	128	12	495
Bart van Lith United States	7	319 0.8×	240 0.8×	131 0.9×	105 0.8×	87 0.7×	8	406
Michael Gulrajani United States	8	542 1.4×	408 1.4×	206 1.4×	162 1.3×	159 1.2×	18	662
Bas van de Kar Netherlands	8	325 0.8×	240 0.8×	129 0.9×	150 1.2×	90 0.7×	10	462
Edwin de Zwart United States	6	252 0.6×	191 0.6×	106 0.7×	104 0.8×	70 0.5×	7	356
Елена Бибикова United States	9	326 0.8×	236 0.8×	153 1.0×	185 1.4×	141 1.1×	16	525
Arnau Montraveta Spain	12	236 0.6×	182 0.6×	119 0.8×	281 2.2×	96 0.8×	17	492
Julie Di Paolo United States	7	190 0.5×	144 0.5×	64 0.4×	78 0.6×	76 0.6×	11	266
Daisy Moreno United States	7	174 0.4×	70 0.2×	201 1.4×	178 1.4×	58 0.5×	9	430
Christina Liu United States	7	147 0.4×	133 0.4×	53 0.4×	240 1.9×	45 0.4×	14	465
Lesley Liu‐Bujalski United States	7	192 0.5×	104 0.3×	70 0.5×	146 1.1×	98 0.8×	10	346

Countries citing papers authored by Fanny Krantz

Since Specialization

Citations

This map shows the geographic impact of Fanny Krantz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanny Krantz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanny Krantz more than expected).

Fields of papers citing papers by Fanny Krantz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanny Krantz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanny Krantz. The network helps show where Fanny Krantz may publish in the future.

Co-authorship network of co-authors of Fanny Krantz

This figure shows the co-authorship network connecting the top 25 collaborators of Fanny Krantz. A scholar is included among the top collaborators of Fanny Krantz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanny Krantz. Fanny Krantz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Gulrajani, Michael, Jean Cheung, Fanny Krantz, et al.. (2023). P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF). HemaSphere. 7(S3). e41702a0–e41702a0. 1 indexed citations

Jurczak, Wojciech, Nagah Elmusharaf, Christopher P. Fox, et al.. (2023). Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. Therapeutic Advances in Hematology. 14. 1564091249–1564091249. 3 indexed citations

Cheung, Jean, Fanny Krantz, Michael Gulrajani, et al.. (2023). P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF). HemaSphere. 7(S3). e281417f–e281417f.

Jurczak, Wojciech, Nagah Elmusharaf, Christopher P. Fox, et al.. (2022). Abstract CT532: Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Cancer Research. 82(12_Supplement). CT532–CT532. 1 indexed citations

Gupta, Puja, Varun R. Shanker, Fanny Krantz, et al.. (2021). Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. Science Translational Medicine. 13(598). 15 indexed citations

Niemann, Carsten Utoft, Helena Mora-Jensen, Eman L. Dadashian, et al.. (2017). Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical Cancer Research. 23(19). 5814–5823. 25 indexed citations

Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations

Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841. 121 indexed citations

Mora-Jensen, Helena, Carsten Utoft Niemann, Michael Gulrajani, et al.. (2016). Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model. Cancer Research. 76(14_Supplement). 4797–4797. 1 indexed citations

10.

Byrd, John C., Jeffrey A. Jones, Richard R. Furman, et al.. (2016). Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7521–7521. 14 indexed citations

11.

Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations

12.

Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2015). The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. Blood. 126(23). 2920–2920. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact